Table 1. Recommended TKI doses approved... | American Society of Hematology

Table 1.

Recommended TKI doses approved for children and proportion of patients achieving MMR

Recommended TKI dose for CML-CP treatment	Proportion of pediatric patients with CML-CP treated with first-line TKI who achieved MMR
Recommended TKI dose for CML-CP treatment	Patients, no.	12 mo	18 mo	24 mo	References
Imatinib
340 mg/m²/dose, once daily	51	NR	NR	NR	16
300 mg/m²/dose, once daily	140	42%*	59%*	69%*	14
260 mg/m²/dose, once daily	44	31%†	55%*	60%*	15
Nilotinib
230 mg/m²/dose, twice daily	25	64%*	68%§	NR	18
Dasatinib
60 mg/m²/dose, once daily	84	52%*	65%*	70%*	17

Recommended TKI dose for CML-CP treatment	Proportion of pediatric patients with CML-CP treated with first-line TKI who achieved MMR
Recommended TKI dose for CML-CP treatment	Patients, no.	12 mo	18 mo	24 mo	References
Imatinib
340 mg/m²/dose, once daily	51	NR	NR	NR	16
300 mg/m²/dose, once daily	140	42%*	59%*	69%*	14
260 mg/m²/dose, once daily	44	31%†	55%*	60%*	15
Nilotinib
230 mg/m²/dose, twice daily	25	64%*	68%§	NR	18
Dasatinib
60 mg/m²/dose, once daily	84	52%*	65%*	70%*	17

NR, not reported.

Results are reported as a cumulative rate at the indicated time point.

Results are reported as a response rate at the indicated time point.

Cumulative response rate by data cutoff at 16.6 mo.